Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET
Company Participants
Joshua Drumm - VP, IR
Thomas Lingelbach - Chairman, President & CEO
Peter Buhler - CFO
Conference Call Participants
Maurice Raycroft - Jefferies
Edward White - H.C. Wainwright & Co.
Boran Wang - Guggenheim Securities
Max Herrmann - Stifel, Nicolaus & Company
Simon Scholes - First Berlin
Samir Devani - Rx Securities Limited
Operator
Good day and thank you for standing by. Welcome to the Valneva 9 Months 2023 Financial Results Call. [Operator Instructions].
I would now like to hand the conference over to your speaker today, Joshua Drumm, VP, Investor Relations. Please go ahead.
Joshua Drumm
Thank you for joining us to discuss Valneva's 9 months 2023 results and corporate update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the 9 months ended September 30, 2023, which were published earlier today available within the Financial Reports section on our Investor website. As always, I'm joined by Valneva's CEO, Thomas Lingelbach; and CFO, Peter Buhler; who will provide an overview and update of our business as well as our key financial results for the first 9 months of the year.
There will be an analyst Q&A session at the conclusion of the prepared remarks. Before we begin, I'd like to remind listeners quickly that during this presentation, we'll be making forward-looking statements, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
You can find additional information about these risks and uncertainties in our periodic filings with the Securities and Exchange Commission and with the French market authority, which are listed on our company website. Please note that today's presentation includes information provided as of today, November 9, 2023 and Valneva undertakes no obligation to revise or update forward-looking statements except as required by applicable securities laws.
With that, it's my pleasure to introduce Thomas to begin today's presentation.
Thomas Lingelbach
Thank you so much, Josh and good day. Welcome to our 9 months financial report and general business update. Let me start with our R&D highlights. We are progressing full steam towards potential licensure of the world's first chikungunya vaccine, where we foresee the PDUFA date towards the end of this month. On Lyme disease, the Phase III study, VALOR with Pfizer continues, cohort 1 completed its first tick season and current cohort 2 is nicely enrolling.